Abstract: A computer system for predicting an anomaly behavior (fraudulent behavior) for a user of a smart shopping cart (physical receptacle). The computer system gathers data associated with a physical activity of the user, the user being physically present at a location of a retailer and adding one or more items from the location of the retailer to the physical receptacle. The computer system applies a computer model to detect, based on the gathered data, one or more anomalies during the physical activity of the user, the one or more anomalies being indicative of the fraudulent behavior. In response to determining that the one or more detected anomalies satisfy a threshold condition for the fraudulent behavior, the computer system sends a communication to a management system of the retailer to cause at least one remedial action to be performed before the user physically leaves the location of the retailer.

Abstract: Methods of using grids in connection with suitable microscopy techniques, such as for determining the structure of target compounds including proteins, are disclosed. Said grid comprising a coating modified with one or more capture agents and a deactivating agent.

Abstract: Grids comprising a coating modified with one or more capture agents and a deactivating agent are disclosed. Methods of using such grids in connection with suitable microscopy techniques, such as for determining the structure of target compounds including proteins, are also disclosed.

Abstract: Methods of using grids in connection with suitable microscopy techniques, such as for determining the structure of target compounds including proteins, are disclosed. Said grid comprising a coating modified with one or more capture agents and a deactivating agent.

Abstract: Grids comprising a coating modified with one or more capture agents and a deactivating agent are disclosed. Methods of using such grids in connection with suitable microscopy techniques, such as for determining the structure of target compounds including proteins, are also disclosed.

Abstract: Antibodies specific for ELAMs are disclosed.

Abstract: The invention relates to aglycosyl anti-CD154 antibodies or antibody derivatives, characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-CD154 antibodies or antibody derivatives thereof.

Abstract: The present invention relates to methods for designing and producing novel CD40:CD154 binding interrupter compounds and methods using these compounds to treat conditions associated with inappropriate CD154 activation in a subject. This invention also relates to novel methods for screening candidate compounds for the properties of specifically binding CD154 and interrupting CD40:CD154 interaction. This invention further relates to methods of improving the binding affinity, or the ability to block CD40/CD154 interaction, of a synthetic molecule for a trimeric protein, such as CD154. These methods comprise converting a first synthetic molecule that cannot promote lattice or aggregate formation of its target trimeric protein to a second synthetic molecule that can promote lattice or aggregate formation of its target trimeric protein.

Abstract: This invention relates to compositions and methods useful for activating LT-? receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-? and multiple subunits of lymphotoxin-?, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-? receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-? receptor which act as lymphotoxin-? receptor activating agents alone or in combination with other lymphotoxin-? receptor activating agents either in the presence or absence of lymphotoxin-?/? complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-? receptor antibodies either alone or in the presence of other lymphotoxin-? receptor activating agents to potentiate tumor cell cytotoxicity.

Abstract: The present invention provides novel ion channel polypeptides and polynucleotides that identify and encode them. In addition, the invention provides expression vectors, host cells and methods for their production. The invention also provides methods for the identification of ion channel agonists/antagonists, useful for the treatment of human diseases and conditions.

Abstract: This invention relates to compositions and methods comprising “lymphotoxin-? receptor blocking agents”, which block lymphotoxin-? receptor signalling. Lymphotoxin-? receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-? receptor extracellular domain that act as lymphotoxin-? receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-? receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-? receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-? receptor signalling is provided.